Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer

The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival

Shionogi launches global Phase 2 trial for late-onset Pompe disease treatment

Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy

Touchlight & NEB launch game-changing benchtop DNA kit

This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development

MedRabbits launches integrated clinic to revolutionize patient care

Rhythm Pharmaceuticals’ Phase 3 EMANATE trial falls short of primary goals

The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes

SK bioscience bags fresh backing to accelerate fight against respiratory disease

RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute

Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI

The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI

Epigenica expands into Japan via PrimeTech partnership

The move opens Japan’s advanced life science market to Epigenica’s high-throughput epigenetic profiling kits

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

LANXESS marks 40 yrs of animal disease defense 'Virkon S'

A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone